Autopsy report · NCT03891615

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 5 years 5 months before it stopped.
20 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Massachusetts General Hospital
Sponsor type: University, hospital or other
Conditions: Lung Cancer
Interventions: Niraparib; Osimertinib
Participants: 20
Sites: 3
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.